Skip to content
Credit reportVerdict and grounds
Made on 22-11-2026 at 15:28
Reference CK-0790439043-20261122

MF PHARMA

ActivePrivate limited company0790.439.043Quai de Rome 48, 4000 Liège
Retail sale of pharmaceutical products (NACE 47730) · founded in 2022 · one director · accounts in the micro format

Sources: the KBO register on 22-11-2026; the National Bank, 2025 annual accounts filed on 14-04-2026; the Belgian Official Gazette, latest deed of 25-03-2026.

Credit verdict
Checked score 2025
The score, from 0 to 100, reflects the bankruptcy probability and the standing among sector peers.
Bankruptcy probability within 12 months
The median of 40,399 micro companies in the retail trade sector (NACE 47) is 0.6%.
Gross margin
€55,691
▼ 5.3% against 2024
Net result
€34,505
▼ 13.6% against 2024
Equity
€15,747
▼ 77.9% against 2024
Cash
€74,094
▼ 6.8% against 2024

Grounds

the facts the verdict rests on, each with its source
  1. MF PHARMA made a profit in every financial year since 2022.Annual accounts 2022 to 2025 page 2
  2. Equity stands at €15,747, or 16.4% of the balance sheet total of €96,029. The solvency of 16.4% is higher than at 35% of the 25,428 companies filing micro accounts in retail trade (NACE 47) in 2025.Annual accounts 2025 page 2
  3. MF PHARMA paid out €90,000 in dividends, 261% of the profit of 2025. Because of the dividend and €55,549 higher other debts due within one year, solvency fell from 73.3% to 16.4%.Annual accounts 2025 page 2
  4. The last four annual accounts came in on time. The 2025 accounts were filed 108 days before the end of the term.National Bank, filing of 14-04-2026 page 4

Representation

The signing rule is in the founding deed of 07-09-2022.

Articles of association, Belgian Official Gazette of 07-09-2022, deed 22355997

Ownership

The accounts in the micro format list no shareholders. holds all 100 shares.

Deed of 07-09-2022

MF PHARMA · 0790.439.043 · credit report of 22-11-2026Page 1 of 5
MF PHARMA0790.439.043 · report of 22-11-2026

Financial situation

Annual accounts 2022 to 2025, as filed with the National Bank

Gross margin and net resultin euro

20228,811202339,410202458,808202555,69120226,944202323,979202439,953202534,505
gross marginnet result

Equity and debtsin euro

202220232024202515,74780,282
equitydebts

Cashin euro

20227,330202337,381202479,493202574,094
on the balance sheet date
Financial year20223 months202320242025Trend
Results
Gross margin€8,811€39,410€58,808€55,691
Operating result€8,761€31,362€50,603€47,968
Net result€6,944€23,979€39,953€34,505
Balance sheet at the closing date
Equity€8,144€31,290€71,242€15,747
Debts€7,172€32,595€25,923€80,282
Debts due after more than one year-€6,882€1,754-
Debts due within one year€7,172€25,713€24,169€80,282
Cash€7,330€37,381€79,493€74,094
Balance sheet total€15,316€63,885€97,165€96,029
Ratios
Solvency53.2%49.0%73.3%16.4%
Liquidity2.141.813.621.17

Source: Annual accounts 2025, micro format, filed on 14-04-2026 (2026-00080257); Annual accounts 2024, micro format, filed on 10-07-2025 (2025-00256372); Annual accounts 2022 to 2023, filed from 11-07-2023 to 10-07-2024 (2023-00229938, 2024-00250739).

Debts rose by €54,360 in 2025, of which €564 to suppliers. A dividend stands among the debts on the balance sheet date until it is paid.

The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.

MF PHARMA states no turnover; the micro format does not require it. The gross margin, what is left after purchases, fell from €58,808 to €55,691.

The financial year to 31-12-2022 ran for 3 months.

MF PHARMA · 0790.439.043 · credit report of 22-11-2026Page 2 of 5
MF PHARMA0790.439.043 · report of 22-11-2026

Board, signature and ownership

Position on 22-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts

Who represents the company

The signing rule is in the founding deed of 07-09-2022.

Articles of association, Belgian Official Gazette of 07-09-2022, deed 22355997

Board

one director in office
Director (not named in the articles)appointed by deed of 07-09-2022
term without a fixed enddeed of 07-09-2022

Ownership and group

Shareholders

The accounts in the micro format list no shareholders. holds all 100 shares.

Deed of 07-09-2022

MF PHARMA · 0790.439.043 · credit report of 22-11-2026Page 3 of 5
MF PHARMA0790.439.043 · report of 22-11-2026

Events and comparison

The last 24 months, newest first

Annual accounts 2025 filed, 108 days before the deadline.

NBB filing

Registered office moved from Liège to LIEGE Quai de Rome. The registered office moved from Au pèrî 24-4000 LIEGE to 4000 LIEGE Quai de Rome 48/51. Board meeting of 03-03-2026.

Gazette, deed 26042229

Annual accounts 2024 filed, 21 days before the deadline.

NBB filing

Highest result from 2022 to 2025. The operating result of €50,603 and the net result of €39,953 are both a record.

Financial

Comparable companies, two years later

In July 2024, 7,983 companies had the same profile as MF PHARMA has now: micro, 2 to 5 years old, solvency 10 to 30% and a profit of 5% of the balance sheet or more. Two years later 94.3% were still trading, 2.0% had stopped another way and 3.7% had gone bankrupt.

still trading 94.3% stopped another way 2.0% bankrupt 3.7%

The return on assets of MF PHARMA, 35.9%, is higher than at 94% of the 24,617 companies filing micro accounts in retail trade (NACE 47) in 2025.

Other findings

Peppol

Reachable for e-invoices since 23-10-2025, under 0208:0790439043.

Sanctions lists

MF PHARMA · 0790.439.043 · credit report of 22-11-2026Page 4 of 5
MF PHARMA0790.439.043 · report of 22-11-2026

Sources and method

Where each fact in this report comes from

SourceWhatDateReference
KBO registerRegistration, legal situation, activity, establishment units22-11-2026KBO 0790.439.043
National Bank of BelgiumAnnual accounts 2025, micro format14-04-20262026-00080257
National Bank of BelgiumAnnual accounts 2024, micro format10-07-20252025-00256372
National Bank of BelgiumAnnual accounts 2022 to 202311-07-2023 to 10-07-20242023-00229938, 2024-00250739
Belgian Official GazetteFounding deed with the articles of association07-09-2022deed 22355997
Peppol DirectoryRegistration for e-invoices23-10-20250208:0790439043
Sanctions lists EU, UN, US (OFAC) and UKComparison of the name19-11-2026
CheckedChecked score, bankruptcy probability, credit, comparable companies21-11-2026bankruptcy model of 21 November 2026

Method

Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.

Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 21 November 2026, computed on 21-11-2026.

Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.

Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.

The scores and ratios are Checked's own calculations, not a credit decision.

MF PHARMA · 0790.439.043 · credit report of 22-11-2026Page 5 of 5